Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-61393215 safety, tolerability, PK and PD study in healthy participants
NL-OMON24181Phase 1Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of rocavorexant in panic disorder and anxiety disorder (2 arms), sponsored by Janssen Pharmaceutical. Planned start Jun 2016; status: not yet recruiting.
02
Drugs
rocavorexant
03
Conditions
panic disorderanxiety disorder
Beyond the preview
Go deeper on NL-OMON24181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24181.